There are now clinically validated and approved CSF tests for AD pathologies and neurodegeneration (161), as well as promising developments in novel biomarkers for α-synuclein and TDP-43 pathologies (8, 133). The gene discussed is TARDBP; the disease is Alzheimer disease.